Rocco Danilo, Della Gravara Luigi, Ragone Angela, Sapio Luigi, Naviglio Silvio, Gridelli Cesare
Department of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, Italy.
Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Cancers (Basel). 2023 Sep 22;15(19):4684. doi: 10.3390/cancers15194684.
Taking into account the huge epidemiologic impact of lung cancer (in 2020, lung cancer accounted for 2,206,771 of the cases and for 1,796,144 of the cancer-related deaths, representing the second most common cancer in female patients, the most common cancer in male patients, and the second most common cancer in male and female patients) and the current lack of recommendations in terms of prognostic factors for patients selection and management, this article aims to provide an overview of the current landscape in terms of currently available immunotherapy treatments and the most promising assessed prognostic biomarkers, highlighting the current state-of-the-art and hinting at future challenges.
考虑到肺癌巨大的流行病学影响（2020年，肺癌病例达2206771例，癌症相关死亡达1796144例，是女性患者中第二常见的癌症、男性患者中最常见的癌症以及男性和女性患者中第二常见的癌症）以及目前在患者选择和管理的预后因素方面缺乏相关建议，本文旨在概述当前可用免疫治疗的现状以及最有前景的评估预后生物标志物，突出当前的技术水平并暗示未来的挑战。
